Home/Filings/4/0001193125-25-317947
4//SEC Filing

Lundberg Sven Ante 4

Accession 0001193125-25-317947

CIK 0001651311other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 6:59 PM ET

Size

26.5 KB

Accession

0001193125-25-317947

Insider Transaction Report

Form 4
Period: 2025-12-12
Lundberg Sven Ante
DirectorPresident, CEO & PEO
Transactions
  • Disposition from Tender

    Common Shares

    2025-12-12$97.00/sh30,297$2,938,8090 total(indirect: By Trust)
  • Disposition from Tender

    Common Shares

    2025-12-12$97.00/sh16,372$1,588,0840 total(indirect: By Trust)
  • Disposition from Tender

    Common Shares

    2025-12-12$97.00/sh9,191$891,5270 total(indirect: By Trust)
  • Disposition from Tender

    Common Shares

    2025-12-12$97.00/sh9,192$891,6240 total(indirect: By Trust)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12312,6200 total
    Exercise: $13.52Exp: 2030-01-03Common Shares (312,620 underlying)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12351,6280 total
    Exercise: $24.43Exp: 2031-02-16Common Shares (351,628 underlying)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12300,0000 total
    Exercise: $41.65Exp: 2035-01-29Common Shares (300,000 underlying)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12360,0000 total
    Exercise: $36.09Exp: 2034-01-31Common Shares (360,000 underlying)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12380,0000 total
    Exercise: $16.07Exp: 2033-02-02Common Shares (380,000 underlying)
  • Disposition to Issuer

    Share Option (right to buy)

    2025-12-12295,0000 total
    Exercise: $24.61Exp: 2032-01-31Common Shares (295,000 underlying)
Footnotes (3)
  • [F1]On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
  • [F2]The indirect holdings represent shares for which the Reporting Person and members of his immediate family are the sole beneficiaries.
  • [F3]This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Documents

1 file

Issuer

Merus N.V.

CIK 0001651311

Entity typeother

Related Parties

1
  • filerCIK 0001682126

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 6:59 PM ET
Size
26.5 KB